Market Overview

UPDATE: Credit Suisse Downgrades Amgen to Neutral; Upgrade Catalysts Have Passed

Share:
Related AMGN
Portfolio Manager Says Now Is A Great Time To Buy Biotech
A Big Biotech ETF Is About To Get Cheaper
Cabozantinib Franchise Will Continue To Transform Exelixis' Fortunes In 2018 (Seeking Alpha)

Credit Suisse downgraded Amgen (NASDAQ: AMGN) from Outperform to Neutral and lowered the price target to $90.00.

Credit Suisse commented, "The principal reason for our downgrade is that the 3 key elements of our July 2012 report entitled "Upgrading to Outperform = Agency cost + operational gearing + defensive macro call" have been realized, in our veiw [sic] (Please refer to our note,"Upgrading to Outperform = Agency cost + Operational gearing + Defensive macro call", published on July 25). We believe investors are likely looking for fundamental (i.e., pipeline and strategy) improvements/triggers in 2013. We have made no changes to our P&L estimates."

Amgen closed at $82.07 on Friday.

Latest Ratings for AMGN

DateFirmActionFromTo
Nov 2017ArgusDowngradesBuyHold
Oct 2017BMO CapitalMaintainsMarket Perform
Oct 2017Morgan StanleyMaintainsOverweight

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (AMGN)

View Comments and Join the Discussion!

Partner Center